

The Isovaleric Acidemia IVA Treatment Global Market Poised For Ascendancy With Anticipated 5.8% CAGR

*The Business Research Company's
Isovaleric Acidemia (IVA) Treatment
Global Market Report 2025 – Market Size,
Trends, And Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, June 18, 2025

/EINPresswire.com/ -- The incredible

growth trajectory of the [isovaleric acidemia IVA treatment market](#) can be ascribed to increasing awareness of rare metabolic disorders, the augmentation of newborn screening programs, surging government funding for orphan diseases, and a rising demand tied to early diagnosis and genetic counseling. In 2024, the market was valued at \$0.60 billion, it is predicted to surge to \$0.63 billion in 2025 marking a compound annual growth rate CAGR of 5.8%.

“

The Business Research
Company's Isovaleric
Acidemia (IVA) Treatment
Global Market Report 2025 –
Market Size, Trends, And
Global Forecast 2025-2034

”

*The Business Research
Company*



The Business
Research Company

The Business Research Company

What Is The Projected Future Growth Of The Isovaleric
Acidemia IVA Treatment Market Size?

In the forecast period, the isovaleric acidemia IVA treatment market is slated to register blistering growth and is set to expand to a staggering \$0.79 billion by 2029 maintaining its CAGR at 5.8%. The momentum for growth during the predicted period can be attributed to a rise in the adoption of innovative gene therapies, increasing investments in rare disease research, numerous

collaborations between biotech firms and research institutes, and improvements in personalized medicine for treating metabolic disorders. Moreover, advancements in screening methodologies for newborns, developing targeted gene editing tools, and the innovation of novel enzyme replacement formulations are some of the defining trends of this period.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=24269&type=smp>

What Are The Key Drivers Propelling The Growth Of The Isovaleric Acidemia IVA Treatment Market?

A crucial driver of the isotonic acidemia IVA treatment market is the escalating prevalence of metabolic disorders. Metabolic disorders disrupt normal metabolic processes, impacting how the body converts food into energy. Isovaleric acidemia treatment assists in managing metabolic disorders by grapple with the buildup of toxic substances in the body, restoring normal metabolic function, and averting complications like neurological damage. For instance, in 2022, around 25.5 million people in the U.S. were diagnosed with diabetes, accounting for 7.6% of the total population, as highlighted by the American Diabetes Association.

Sustained awareness of rare genetic disorders is anticipated to fuel the market, supported by improved diagnosis techniques and comprehensive early detection. Consequently, isovaleric acidemia treatment, which reduces the buildup of toxic metabolites and mitigates metabolic crises, becomes a vital requirement.

What Key Player Strategies Are Driving The Isovaleric Acidemia IVA Treatment Market?

Major contributors to the isovaleric acidemia IVA treatment market include Nestlé Health Science S.A., BioMarin Pharmaceutical Inc., GenScript Biotech Corporation, Nutricia Advanced Medical Nutrition, Rocket Pharmaceuticals Inc., REGENXBIO Inc., uniQure N.V., Vitaflo International Ltd., Orchard Therapeutics plc, Editas Medicine Inc., Cambrooke Therapeutics Inc., Recordati Rare Diseases Inc., Abbott Nutrition, Targeted Medical Pharma Inc., Solace Nutrition LLC, Nutricia Metabolics, Bluebird Bio Inc., Verve Therapeutics Inc., Abeona Therapeutics Inc., and CRISPR Therapeutics AG.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/isovaleric-acidemia-iva-treatment-global-market-report>

How Is The [Isovaleric Acidemia IVA Treatment Market Segmented?](#)

The isovaleric acidemia IVA treatment market can be divided into segments based on:

Segments:

1. By Type:

- o Classical Isovaleric Acidemia
- o Moderate Isovaleric Acidemia
- o Non-classical Isovaleric Acidemia

2. By Treatment:

- o Dietary Management
- o Enzyme Replacement Therapy
- o Gene Therapy
- o Pharmacological Treatment

3. By Route of Administration:

- o Oral

- o Injectable

Subsegments:

1. For Classical Isovaleric Acidemia:

- o Dietary Management
- o Carnitine Supplementation
- o Glycine Supplementation
- o Emergency Management
- o Gene Therapy (Investigational)

2. For Non-classical Isovaleric Acidemia:

- o Observation and Preventive Care
- o Mild Dietary Modifications
- o Occasional Supplementation
- o Genetic Counseling and Monitoring

What Are The Regional Insights In The Isovaleric Acidemia IVA Treatment Market?

In 2024, North America held the largest share of the isovaleric acidemia IVA treatment market. Asia-Pacific is projected to witness the fastest growth during the forecast period. The report includes regional analysis for Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Similar Reports By [The Business Research Company](https://www.thebusinessresearchcompany.com/):

Cardiometabolic Diseases Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report>

Comprehensive Metabolic Panel (CMP) Testing Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/comprehensive-metabolic-panel-cmp-testing-global-market-report>

Amino Acid Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/amino-acid-global-market-report>

About The Business Research Company

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info

This press release can be viewed online at: <https://www.einpresswire.com/article/823267555>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.